Evidence map›Paper›PMID 39502069›Full record

ArticlePediatric blood & cancer2025

Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Sara Kreimer, Wei Xue, Amira Qumseya, Timothy B Lautz, Archana Shenoy, Susan Hiniker, Dana Casey, Rajkumar Venkatramani, Carola Arndt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara KreimerDivision of Pediatric Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, California, USA.
Wei XueCOG Data Center, University of Florida, Gainesville, Florida, USA.
Amira QumseyaCOG Data Center, University of Florida, Gainesville, Florida, USA.
Timothy B LautzDepartment of Surgery, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-3323-6509
Archana ShenoyDepartment of Pathology, The Ohio State University and Nationwide Children's Hospital, Columbus, Ohio, USA.
Susan HinikerDepartment of Radiation Oncology, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0003-4723-2151
Dana CaseyDepartment of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0001-6851-7653
Rajkumar VenkatramaniDivision of Pediatric Hematology-Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Carola ArndtDivision of Pediatric Hematology-Oncology, Mayo Alix School of Medicine, Rochester, New York, USA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
National Institutes of Health with NCTN Operations Center Grant U10CA180886NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCTN Statistics & Data Center Grant U10CA180899St. Baldrick's Foundation
6 · The paper itself

Abstract

Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1. A late event occurred in 2.9% of 5-year event-free survivors supporting guidelines to limit surveillance for these events to 5 years from diagnosis.

Indexed as

RhabdomyosarcomaAdolescentCancer SurvivorsChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantMaleNeoplasm Recurrence, LocalNeoplasms, Second PrimarySurvival Ratelate eventsrhabdomyosarcoma

Identifiers

PMID39502069
PMCPMC12503035

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.